Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 20, 2022

SELL
$0.79 - $5.98 $797 - $6,039
-1,010 Closed
0 $0
Q1 2022

Apr 05, 2022

SELL
$4.25 - $10.4 $11,900 - $29,120
-2,800 Reduced 73.49%
1,010 $6,000
Q4 2021

Feb 22, 2022

BUY
$9.68 - $17.74 $36,880 - $67,589
3,810 New
3,810 $37,000

Others Institutions Holding RUBY

About Rubius Therapeutics, Inc.


  • Ticker RUBY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,357,000
  • Description
  • Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...
More about RUBY
Track This Portfolio

Track Byrne Asset Management LLC Portfolio

Follow Byrne Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Byrne Asset Management LLC with notifications on news.